SBL
LOGC

Sargent Bickham Lagudis’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Sargent Bickham Lagudis’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$1K – 1027
2021
Q1 		$1K Hold
100
– – ﹤0.01% 922
2020
Q4 		$1K Hold
100
– – ﹤0.01% 859
2020
Q3 		$1K Buy
+100
New +$759 ﹤0.01% 779

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Sargent Bickham Lagudis's LOGC Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 100 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in LOGC in Q3 2020 and held it in 3 quarters. The position peaked at $1K in Q1 2021. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 100 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Sargent Bickham Lagudis's LogicBio Therapeutics, Inc. Common Stock position peaked at $1K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.